儿童急性T细胞白血病嵌合抗原受体研究进展  

Progress of chimeric antigen receptor in childhood acute T-lymphoblastic leukemia

作　　者：何红波(综述) 高超(审校)[1] 郑胡镛(审校)[1] He Hongbo;Gao Chao;Zheng Huyong(Hematology Center,Beijing Key Laboratory of Pediatric Hematology Oncology,National Key Discipline of Pediatrics(Capital Medical University),Key Laboratory of Major Diseases in Children,Ministry of Education,Beijing Children′s Hospital,Capital Medical University,National Center for Children′s Health,Beijing 100045,China)

机构地区：[1]国家儿童医学中心,首都医科大学附属北京儿童医院血液病中心,儿童血液病与肿瘤分子分型北京市重点实验室,儿科学国家重点学科,儿科重大疾病研究教育部重点实验室,100045

出　　处：《国际儿科学杂志》2022年第1期1-5,共5页International Journal of Pediatrics

基　　金：国家自然科学基金(82070154);国家科技重大专项(2017ZX09304029004)。

摘　　要：急性淋巴细胞白血病(acute lymphoblastic leukemia,ALL)是儿童时期最常见的恶性肿瘤,其中急性T淋巴细胞白血病(T-ALL)占儿童ALL的10%~15%。随着MICM分型、危险度分层及多药联合强化疗的应用,T-ALL患儿的预后已得到改善,但总生存率和无事件生存率仍<70%,复发/难治T-ALL总生存率<10%。CDl9嵌合抗原受体(chimeric antigen receptor,CAR)修饰的T细胞治疗儿童难治性复发B-ALL缓解率已达70%~90%,但CAR在难治复发T-ALL中仍面临许多挑战。随着CAR-T细胞及CAR-NK细胞靶向治疗的出现及应用,复发/难治T-ALL的预后将有望得到改善。Acute lymphoblastic leukemia(ALL)is the most common malignant tumor in childhood,and T-ALL accounts for 10%~15%of all in children with ALL.Based on the application of MICM classification,risk stratification and multi-drugs intensive therapy,the prognosis of children with T-ALL has been improved,but the overall survival rate and event free survival rate are still less than 70%,and the overall survival rate of relapsed/refractory T-ALL is less than 10%.The treatment of T-ALL in children still faces great challenges.CDl9 targeted chimeric antigen receptor(CAR)modified T cells have shown impressive results in children with refractory B-ALL,with remission rate of 70%~90%.The emergence of CAR-T and CAR modified NK cells(CAR-NK)targeted therapy is expected to improve the prognosis of T-ALL in children.This article reviews the latest progress of CAR-T and CAR-NK in children with T-ALL.

关 键 词：儿童 急性淋巴细胞白血病 嵌合抗原受体 

分 类 号：R73[医药卫生—肿瘤]